Response of BRCA1-mutated gallbladder cancer to olaparib: A case report.

Related Articles

Response of BRCA1-mutated gallbladder cancer to olaparib: A case report.

World J Gastroenterol. 2016 Dec 14;22(46):10254-10259

Authors: Xie Y, Jiang Y, Yang XB, Wang AQ, Zheng YC, Wan XS, Sang XT, Wang K, Zhang DD, Xu JJ, Li FG, Zhao HT

Abstract
Gallbladder cancer (GBC), although considered as a relatively rare malignancy, is the most common neoplasm of the biliary tract system. The late diagnosis and abysmal prognosis present challenges to treatment. The overall 5-year survival rate for metastatic GBC patients is extremely low. BRCA1 and BRCA2 are the breast cancer susceptibility genes and their mutation carriers are at a high risk for cancer development, both in men and women. Olaparib, an oral poly ADP-ribose polymerase inhibitor, has been approved by the Food and Drug Administration and the European Commission for the treatment of ovarian cancer with any BRCA1/2 mutations. The first case of a BRCA1-mutated GBC patient who responded to olaparib treatment is reported here.

PMID: 28028375 [PubMed - indexed for MEDLINE]

http://ift.tt/2t5wyLO